Developing pioneering drugs against serious treatment complications

Icelandic innovation is making strides in the fight against cancer, with Akthelia Pharmaceutical leading the development of a groundbreaking drug aimed at mitigating the severe side effects of chemotherapy. The company is preparing for the first clinical trials of AKT-011, a pioneering medication designed to shield the digestive tract's mucous membranes from the damaging effects of cancer treatments. This initiative addresses a critical unmet need, as approximately 20% of patients undergoing cancer therapy suffer from debilitating gastrointestinal complications.

Dr. Markus Gerhard, a professor at the Technical University of Munich and a member of Akthelia's scientific advisory board, highlighted the unique approach of AKT-011. Unlike conventional treatments that target rapidly dividing cells indiscriminately, AKT-011 focuses on protecting healthy tissues. This innovative strategy could potentially be the first therapy specifically designed to combat this common and severe problem, offering a significant improvement in the quality of life for cancer patients during their treatment.

Beyond AKT-011, Akthelia is also advancing the IN-ARMOR project, which seeks to enhance the body's innate immune responses to infections. This forward-thinking research aims to reduce reliance on antibiotics, a crucial step in combating the growing global challenge of antibiotic resistance. The project has secured substantial funding, including a €900 million grant from the European Union, underscoring its potential impact and the collaborative effort involving numerous research institutions and companies. From an Icelandic perspective, this represents a significant contribution to global health, showcasing the nation's capacity for cutting-edge biomedical research and development.

“

There is a great need in medicine for new solutions that can reduce the serious complications of cancer treatment. What is particularly interesting about AKT-011 is that the solution is based on a different approach than has been taken so far.